Replies to post #139055 on Biotech Values

[DewDiligence]

THRX/GSK—Relovair is not shaping up to be a shoo-in for the “Son of Advair” that GSK was hoping for when it inked the development deal for this product:

http://www.reuters.com/article/2012/03/23/us-glaxosmithkline-relovair-idUSBRE82M0K720120323

The new once-a-day inhaled medicine showed superiority to GSK's existing twice-daily drug Advair in one trial for chronic lung disease, but not another. That patchy record echoes results of other studies in an extensive development program.

THRX is nevertheless up slightly in trading today. The data could have been a lot worse.